IRIS
AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.789
AS - Asia 8.475
EU - Europa 2.687
SA - Sud America 1.500
AF - Africa 413
Continente sconosciuto - Info sul continente non disponibili 267
OC - Oceania 19
Totale 28.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.473
SG - Singapore 5.322
CN - Cina 1.320
BR - Brasile 1.235
VN - Vietnam 801
IT - Italia 660
FI - Finlandia 445
IE - Irlanda 325
NG - Nigeria 272
HK - Hong Kong 270
DE - Germania 263
FR - Francia 198
CA - Canada 189
GB - Regno Unito 181
IN - India 163
NL - Olanda 143
SE - Svezia 109
AR - Argentina 108
RU - Federazione Russa 84
BD - Bangladesh 79
TR - Turchia 72
MX - Messico 63
IQ - Iraq 55
IL - Israele 49
ID - Indonesia 48
BE - Belgio 45
UA - Ucraina 40
EC - Ecuador 38
JP - Giappone 37
PK - Pakistan 35
ES - Italia 33
CO - Colombia 32
PL - Polonia 32
EG - Egitto 31
PH - Filippine 31
ZA - Sudafrica 30
VE - Venezuela 27
KE - Kenya 21
MK - Macedonia 20
IR - Iran 19
JO - Giordania 19
UZ - Uzbekistan 19
JM - Giamaica 18
CL - Cile 17
MA - Marocco 16
NP - Nepal 16
PY - Paraguay 16
AU - Australia 15
DZ - Algeria 14
MY - Malesia 14
SA - Arabia Saudita 14
RO - Romania 13
AE - Emirati Arabi Uniti 12
CZ - Repubblica Ceca 12
PE - Perù 12
AL - Albania 10
AZ - Azerbaigian 10
KR - Corea 10
CH - Svizzera 9
AT - Austria 8
CR - Costa Rica 8
KZ - Kazakistan 8
LT - Lituania 8
TN - Tunisia 8
UY - Uruguay 8
ET - Etiopia 7
GR - Grecia 7
OM - Oman 7
RS - Serbia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DO - Repubblica Dominicana 6
LB - Libano 6
PA - Panama 6
BG - Bulgaria 5
HN - Honduras 5
MD - Moldavia 5
TW - Taiwan 5
BB - Barbados 4
HU - Ungheria 4
LV - Lettonia 4
NI - Nicaragua 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AM - Armenia 3
BO - Bolivia 3
KW - Kuwait 3
MN - Mongolia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
PT - Portogallo 3
BS - Bahamas 2
BW - Botswana 2
EE - Estonia 2
GD - Grenada 2
GT - Guatemala 2
GY - Guiana 2
HR - Croazia 2
KG - Kirghizistan 2
Totale 27.852
Salva come PNG Salva come JPEG
Città #
Singapore 2.531
Chandler 1.920
Wilmington 1.655
Ashburn 968
The Dalles 729
San Mateo 689
San Jose 592
Dallas 571
Ann Arbor 530
Shanghai 527
Council Bluffs 443
Helsinki 441
New York 401
Boardman 379
Beijing 361
Dublin 322
Leawood 310
Princeton 300
Lawrence 288
Milan 275
Benin City 271
Ho Chi Minh City 259
Hong Kong 247
Hanoi 224
Santa Clara 190
Paris 161
Los Angeles 140
Woodbridge 137
Fairfield 133
Amsterdam 115
São Paulo 112
Rome 108
Toronto 101
Seattle 81
London 79
Columbus 61
Phoenix 57
San Diego 52
Buffalo 48
Orem 47
Da Nang 44
Brussels 43
Rio de Janeiro 42
Kocaeli 39
Falkenstein 38
Norwalk 34
Houston 33
Brooklyn 31
Tokyo 30
Haiphong 29
Moscow 29
Chicago 27
Falls Church 27
Pune 27
Philadelphia 26
Belo Horizonte 25
Curitiba 25
Naples 25
Chennai 24
Manchester 24
Miami 24
Warsaw 24
Frankfurt am Main 23
Atlanta 22
Mexico City 22
San Francisco 22
Baghdad 21
Boston 21
Charlotte 21
Porto Alegre 20
Figino 19
Montreal 19
Brasília 18
Nairobi 18
Stockholm 17
Hải Dương 16
The Bronx 16
Amman 15
Cambridge 15
Campinas 15
Denver 15
Monmouth Junction 15
Salvador 15
Washington 15
Assago 14
Fortaleza 14
Johannesburg 14
Las Vegas 14
Mumbai 14
Munich 14
Tashkent 14
Turin 14
Des Moines 13
Dhaka 13
Newark 13
Austin 12
Buenos Aires 12
Poplar 12
Redwood City 12
Reston 12
Totale 18.136
Salva come PNG Salva come JPEG
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 225
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? 192
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 169
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 159
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 152
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 147
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 145
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 142
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 142
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 136
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 135
A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019 131
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 130
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 129
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 126
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 121
Mapping the human genetic architecture of COVID-19 120
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 117
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 117
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 117
The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment 116
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 116
Daclatasvir for the treatment of chronic hepatitis C 116
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 116
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 115
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 115
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 114
Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients 114
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 113
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 113
From current status to optimization of HCV treatment: Recommendations from an expert panel 113
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients 113
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 112
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 112
Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization 111
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 110
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 108
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 107
Real life experiences in HCV management in 2018 107
Recommendations for the management of hepatitis C virus infection among people who inject drugs 107
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy 107
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 106
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 106
EASL Recommendations on Treatment of Hepatitis C 2014 106
Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C 106
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 106
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 105
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 105
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 105
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 104
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 102
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 102
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 102
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 102
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 102
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 101
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 101
High mortality in COVID-19 patients with mild respiratory disease 101
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 100
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 100
Contribution of beta-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease 100
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 99
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 99
Hepatitis C virus post-exposure prophylaxis: A reasonable option in the era of pangenotypic direct-acting antivirals? 98
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 98
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 98
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature 98
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 97
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 97
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 97
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? 97
Safety of vedolizumab in liver transplant recipients: A systematic review 97
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 96
Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes 96
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 96
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 95
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 95
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 94
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 94
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 94
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 93
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 93
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 93
Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery 93
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 92
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 92
High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study 92
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 91
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 91
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies 91
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 91
An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study 90
New horizons in hepatitis C antiviral therapy with direct-acting antivirals 90
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 90
Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir 90
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method 90
Are We Ready to Discontinue Hepatitis B Immunoglobulins to Prevent Hepatitis B and D Recurrence in Liver Transplant Recipients? 90
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 89
Directly acting antivirals for the treatment of chronic hepatitis C: Unresolved topics from registration trials 89
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 89
Totale 10.923
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.567
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.567
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.612 0 18 59 359 20 21 77 221 121 197 405 114
2022/20234.749 675 211 459 563 430 409 7 418 877 362 273 65
2023/20242.682 184 263 549 130 103 422 149 153 38 46 250 395
2024/20253.997 118 102 51 88 96 417 286 500 551 906 459 423
2025/202610.269 1.484 628 640 876 225 408 3.173 638 560 619 351 667
2026/20271.679 792 887 0 0 0 0 0 0 0 0 0 0
Totale 28.150